Toyama Chemical Launches Phase I Clinical Trials of Anti-rheumatic Agent T-5224.
A low-molecular compound that inhibits an activator protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA.
The development of T-5224 has been sponsored by the Japan Science and Technology Agency.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jun 23, 2006|
|Previous Article:||Mebix, So-net M3 to Form Business Alliance.|
|Next Article:||Riken Discovers New Mechanism for Controlling Allergic Reactions.|